vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $26.2M, roughly 1.8× BCB BANCORP INC). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -49.7%, a 44.9% gap on every dollar of revenue. On growth, BCB BANCORP INC posted the faster year-over-year revenue change (13.1% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $34.9M). Over the past eight quarters, BCB BANCORP INC's revenue compounded faster (1.8% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
BCBP vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $47.7M |
| Net Profit | $-12.0M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | 14.3% |
| Net Margin | -49.7% | -4.8% |
| Revenue YoY | 13.1% | -47.3% |
| Net Profit YoY | -467.6% | -200.9% |
| EPS (diluted) | $-0.73 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $47.7M | ||
| Q3 25 | $26.5M | $122.1M | ||
| Q2 25 | $25.2M | $85.2M | ||
| Q1 25 | $23.8M | $41.1M | ||
| Q4 24 | $23.1M | $90.5M | ||
| Q3 24 | $26.2M | $91.6M | ||
| Q2 24 | $20.4M | $94.4M | ||
| Q1 24 | $25.3M | $74.9M |
| Q4 25 | $-12.0M | $-2.3M | ||
| Q3 25 | $4.3M | $40.1M | ||
| Q2 25 | $3.6M | $23.6M | ||
| Q1 25 | $-8.3M | $-37.4M | ||
| Q4 24 | $3.3M | $2.3M | ||
| Q3 24 | $6.7M | $3.6M | ||
| Q2 24 | $2.8M | $-860.0K | ||
| Q1 24 | $5.9M | $-4.2M |
| Q4 25 | -71.9% | 14.3% | ||
| Q3 25 | 21.9% | 61.8% | ||
| Q2 25 | 19.9% | 53.2% | ||
| Q1 25 | -49.2% | -70.7% | ||
| Q4 24 | 19.9% | 34.8% | ||
| Q3 24 | 35.7% | 28.0% | ||
| Q2 24 | 19.5% | 26.5% | ||
| Q1 24 | 33.0% | 14.7% |
| Q4 25 | -49.7% | -4.8% | ||
| Q3 25 | 16.1% | 32.8% | ||
| Q2 25 | 14.2% | 27.7% | ||
| Q1 25 | -35.0% | -90.9% | ||
| Q4 24 | 14.1% | 2.5% | ||
| Q3 24 | 25.5% | 4.0% | ||
| Q2 24 | 13.8% | -0.9% | ||
| Q1 24 | 23.2% | -5.6% |
| Q4 25 | $-0.73 | $0.01 | ||
| Q3 25 | $0.22 | $0.23 | ||
| Q2 25 | $0.18 | $0.14 | ||
| Q1 25 | $-0.51 | $-0.23 | ||
| Q4 24 | $0.17 | $0.03 | ||
| Q3 24 | $0.36 | $0.02 | ||
| Q2 24 | $0.14 | $-0.01 | ||
| Q1 24 | $0.32 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $-261.8M |
| Total Assets | $3.3B | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $215.5M | ||
| Q3 25 | — | $140.4M | ||
| Q2 25 | — | $92.9M | ||
| Q1 25 | — | $108.5M | ||
| Q4 24 | — | $88.6M | ||
| Q3 24 | — | $88.2M | ||
| Q2 24 | — | $105.5M | ||
| Q1 24 | — | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $304.3M | $-261.8M | ||
| Q3 25 | $318.5M | $-264.2M | ||
| Q2 25 | $315.7M | $-308.2M | ||
| Q1 25 | $314.7M | $-334.1M | ||
| Q4 24 | $323.9M | $-301.3M | ||
| Q3 24 | $328.1M | $-311.3M | ||
| Q2 24 | $320.7M | $-321.7M | ||
| Q1 24 | $320.1M | $-330.5M |
| Q4 25 | $3.3B | $396.9M | ||
| Q3 25 | $3.4B | $396.1M | ||
| Q2 25 | $3.4B | $342.9M | ||
| Q1 25 | $3.5B | $327.2M | ||
| Q4 24 | $3.6B | $350.9M | ||
| Q3 24 | $3.6B | $389.5M | ||
| Q2 24 | $3.8B | $395.6M | ||
| Q1 24 | $3.8B | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $74.6M |
| Free Cash FlowOCF − Capex | $34.9M | $74.6M |
| FCF MarginFCF / Revenue | 133.3% | 156.3% |
| Capex IntensityCapex / Revenue | 4.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $74.6M | ||
| Q3 25 | $8.7M | $47.6M | ||
| Q2 25 | $10.3M | $-15.1M | ||
| Q1 25 | $5.0M | $20.0M | ||
| Q4 24 | $67.7M | $15.2M | ||
| Q3 24 | $43.5M | $9.9M | ||
| Q2 24 | $8.1M | $33.5M | ||
| Q1 24 | $8.3M | $45.0M |
| Q4 25 | $34.9M | $74.6M | ||
| Q3 25 | $8.5M | $47.6M | ||
| Q2 25 | $10.2M | $-15.1M | ||
| Q1 25 | $4.7M | $19.9M | ||
| Q4 24 | $66.5M | — | ||
| Q3 24 | $43.4M | $9.9M | ||
| Q2 24 | $8.1M | $33.4M | ||
| Q1 24 | $8.1M | $44.9M |
| Q4 25 | 133.3% | 156.3% | ||
| Q3 25 | 32.0% | 39.0% | ||
| Q2 25 | 40.4% | -17.7% | ||
| Q1 25 | 19.8% | 48.4% | ||
| Q4 24 | 287.5% | — | ||
| Q3 24 | 166.0% | 10.8% | ||
| Q2 24 | 39.6% | 35.4% | ||
| Q1 24 | 32.3% | 60.0% |
| Q4 25 | 4.0% | 0.0% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 0.6% | 0.0% | ||
| Q1 25 | 1.2% | 0.1% | ||
| Q4 24 | 5.3% | 0.0% | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.2% | 0.1% | ||
| Q1 24 | 0.6% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | 1.19× | ||
| Q2 25 | 2.90× | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | 6.74× | ||
| Q3 24 | 6.53× | 2.71× | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
